Maryam B. Lustberg

Risk of Recurrence in Patients with HR+/HER2− Early Breast Cancer: A Podcast

Within 20 years of diagnosis, up to 27% of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative early breast cancer will experience recurrence, despite standard-of-care treatments. Of these recurrences, approximately half will occur within 5 y...